Nuveen
SLN icon

Nuveen’s Silence Therapeutics SLN Stock Holding History

Nuveen’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.23K Buy
+114
New +$1.39K ﹤0.01% 4905

Other funds holding SLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Nuveen's SLN Position: Q3 2026 in Review

Nuveen opened a new position in Silence Therapeutics (SLN) in Q3 2026: 114 shares worth $1.23K. The stake represents ﹤0.01% of the portfolio and ranks #4905 among its holdings.

20 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Nuveen held 114 shares of Silence Therapeutics worth $1.23K as of Q3 2026.
  • Silence Therapeutics was a new Nuveen position in Q3 2026.
  • Silence Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4905 holding.
  • 20 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.